159 related articles for article (PubMed ID: 35657850)
1. The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines.
Villanueva P; Wadia U; Crawford NW; Messina NL; Kollmann TR; Lucas M; Manning L; Richmond P; Pittet LF; Curtis N
PLoS One; 2022; 17(6):e0268042. PubMed ID: 35657850
[TBL] [Abstract][Full Text] [Related]
2. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe.
Geldenhuys HD; Mearns H; Foster J; Saxon E; Kagina B; Saganic L; Jarrahian C; Tameris MD; Dintwe OB; Van Rooyen M; Luabeya KK; Hussey G; Scriba TJ; Hatherill M; Zehrung D
Vaccine; 2015 Sep; 33(37):4719-26. PubMed ID: 25862299
[TBL] [Abstract][Full Text] [Related]
4. A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines.
van Balveren L; van Puijenbroek EP; Davidson L; van Hunsel F
Br J Clin Pharmacol; 2023 Jul; 89(7):2113-2121. PubMed ID: 36717367
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
Pittet LF; Cox L; Freyne B; Germano S; Bonnici R; Gardiner K; Donath S; Collins CL; Casalaz D; Robins-Browne R; Flanagan KL; Messina NL; Curtis N
Vaccine; 2022 Feb; 40(9):1334-1341. PubMed ID: 35105495
[TBL] [Abstract][Full Text] [Related]
6. Adverse events following immunisation with bacille Calmette-Guérin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine.
Hendry AJ; Dey A; Beard FH; Khandaker G; Hill R; Macartney KK
Commun Dis Intell Q Rep; 2016 Dec; 40(4):E470-E474. PubMed ID: 28043221
[TBL] [Abstract][Full Text] [Related]
7. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports.
Mohamed L; Madsen AMR; Schaltz-Buchholzer F; Ostenfeld A; Netea MG; Benn CS; Kofoed PE
BMC Infect Dis; 2021 Dec; 21(1):1264. PubMed ID: 34930152
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
10. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
11. First case of redness and erosion at bacillus Calmette-Guérin inoculation site after vaccination against influenza.
Kondo M; Goto H; Yamamoto S
J Dermatol; 2016 Oct; 43(10):1229-1231. PubMed ID: 27028876
[No Abstract] [Full Text] [Related]
12. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
Squarcione S; Sgricia S; Biasio LR; Perinetti E
Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
[TBL] [Abstract][Full Text] [Related]
13. Active SMS-based influenza vaccine safety surveillance in Australian children.
Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
[TBL] [Abstract][Full Text] [Related]
14. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial.
Nissen TN; Birk NM; Smits G; Jeppesen DL; Stensballe LG; Netea MG; van der Klis F; Benn CS; Pryds O;
Vaccine; 2017 Apr; 35(16):2084-2091. PubMed ID: 28318766
[TBL] [Abstract][Full Text] [Related]
15. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial.
Pittet LF; Moore CL; McDonald E; Barry S; Bonten M; Campbell J; Croda J; Dalcolmo M; Davidson A; Douglas MW; Gardiner K; Gwee A; Jardim B; Lacerda MVG; Lucas M; Lynn DJ; Manning L; de Oliveira RD; Perrett KP; Prat-Aymerich C; Richmond PC; Rocha JL; Rodriguez-Baño J; Warris A; Wood NJ; Messina NL; Curtis N;
EClinicalMedicine; 2023 Oct; 64():102203. PubMed ID: 37719417
[TBL] [Abstract][Full Text] [Related]
17. Erythema at the bacillus Calmette-Guerin scar after influenza vaccination.
Chavarri-Guerra Y; Soto-Perez-de-Celis E
Rev Soc Bras Med Trop; 2019; 53():e20190390. PubMed ID: 31859956
[No Abstract] [Full Text] [Related]
18. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guérin vaccination: A national surveillance study in Japan from 2013 to 2017.
Okuno H; Satoh H; Morino S; Arai S; Ochiai M; Fujita K; Naito S; Kato A; Ishii K; Oishi K; Suzuki M; Tanaka-Taya K
Vaccine; 2022 Aug; 40(33):4922-4928. PubMed ID: 35690499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
